Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 6/20 | 0.51 |
| ▸ | CTSK | P43235 | 6/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 2/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.43 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.41 |
| ▸ | MAP1LC3A | Q9H492 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31703417 | 0.94 | CTSS (0.50) | CTSSCTSKPTPN1TACR1SCN9A | |
| SCHEMBL19720254 | 0.86 | TACR1 (0.48) | CTSSCTSKTACR1SCN9AMAP1LC3B | |
| SCHEMBL31689503 | 0.86 | TACR1 (0.48) | CTSSCTSKTACR1SCN9AMAP1LC3B | |
| SCHEMBL10189374 | 0.85 | CTSS (0.46) | CTSSCTSKTACR1SCN9AMAP1LC3B | |
| SCHEMBL15856127 | 0.85 | CTSS (0.51) | CTSSCTSKTACR1SCN9AMAP1LC3B | |
| SCHEMBL19720234 | 0.85 | CTSS (0.46) | CTSSCTSKTACR1SCN9AMAP1LC3B | |
| SCHEMBL15856090 | 0.85 | CTSS (0.46) | CTSSCTSKTACR1SCN9AMAP1LC3B | |
| SCHEMBL15856088 | 0.85 | CTSS (0.46) | CTSSCTSKTACR1SCN9AMAP1LC3B | |
| SCHEMBL2894889 | 0.84 | CTSS (0.50) | CTSSCTSKPTPN1TACR1SCN9A | |
| SCHEMBL2898437 | 0.84 | CTSS (0.50) | CTSSCTSKPTPN1TACR1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130190529-A1 | Fluorine Radiolabelling Process | ISIS INNOVATION LIMITED (GB) | 2013-07-25 | — | — | US | disclosed |
| US-20130190529-A1 | Fluorine Radiolabelling Process | ISIS INNOVATION LIMITED (GB) | 2013-07-25 | — | — | US | disclosed |
| WO-2012004567-A2 | FLUORINE RADIOLABELLING PROCESS | ISIS INNOVATION LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190529-A1 | Fluorine Radiolabelling Process | ESRRG, NR5A2, RXFP4 | CTSS 2694/4885CTSK 2408/4885PTPN1 4113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.